Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors

Abstract Context The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. Objective We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. Methods We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. Results Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. Conclusion We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required.

[1]  S. Tsoka,et al.  Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action , 2021, European journal of immunology.

[2]  H. Furuta,et al.  Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors. , 2020, Endocrine journal.

[3]  H. Sakura,et al.  Type 1 Diabetes, ACTH Deficiency, and Hypothyroidism Simultaneously Induced by Nivolumab Therapy in a Patient with Gastric Cancer: A Case Report , 2020, Case Reports in Oncology.

[4]  M. Akiyama,et al.  Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study , 2020, Journal for ImmunoTherapy of Cancer.

[5]  K. Ohe,et al.  Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. , 2020, European journal of cancer.

[6]  Yutaka Takahashi,et al.  MECHANISMS IN ENDOCRINOLOGY: Autoimmune hypopituitarism: novel mechanistic insights. , 2020, European journal of endocrinology.

[7]  M. Nishi,et al.  Comparative analysis of human leucocyte antigen between idiopathic and anti‐PD‐1 antibody induced isolated adrenocorticotropic hormone deficiency: A pilot study , 2019, Clinical endocrinology.

[8]  G. Di Dalmazi,et al.  Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment , 2019, Expert review of endocrinology & metabolism.

[9]  R. Scolyer,et al.  Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes. , 2019, The Journal of clinical endocrinology and metabolism.

[10]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[11]  F. Albarel,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. , 2019, European journal of endocrinology.

[12]  A. Imagawa,et al.  Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. , 2019, Endocrine journal.

[13]  C. Mascaux,et al.  Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. , 2019, Clinical lung cancer.

[14]  T. Shiba,et al.  Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy. , 2019, Endocrine journal.

[15]  G. Hasegawa,et al.  Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature , 2019, Journal of Medical Case Reports.

[16]  Y. Kudva,et al.  Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes , 2019, BMJ Open Diabetes Research & Care.

[17]  F. Hodi,et al.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. , 2018, Endocrine reviews.

[18]  R. Sullivan,et al.  High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma , 2018, Cancer.

[19]  Mark S. Anderson,et al.  Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors , 2018, Diabetes.

[20]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[21]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[22]  W. Barry,et al.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA Oncology.

[23]  Tae Yong Kim,et al.  Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer , 2018, Oncoimmunology.

[24]  J. Bertherat,et al.  Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma , 2017, Journal of the Endocrine Society.

[25]  S. Fukushima,et al.  Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma , 2015, Cancer Chemotherapy and Pharmacology.

[26]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[27]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[28]  J. Grob,et al.  Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. , 2015, European journal of endocrinology.

[29]  R. Sullivan,et al.  Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. , 2014, The Journal of clinical endocrinology and metabolism.

[30]  N. Ibrahim,et al.  Ipilimumab-induced autoimmune adrenalitis. , 2013, The lancet. Diabetes & endocrinology.

[31]  A. Imagawa,et al.  Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute‐onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012) , 2012, Journal of diabetes investigation.

[32]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[33]  H. Itoh,et al.  Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. , 2011, Endocrine journal.

[34]  Y. Seino,et al.  Utility of indices using C‐peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes , 2011, Journal of diabetes investigation.

[35]  T. Kobayashi,et al.  Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset , 2009, Diabetologia.

[36]  R. Osman,et al.  Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice , 2008, Proceedings of the National Academy of Sciences.

[37]  S. Rosenberg,et al.  Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis , 2007, Journal of immunotherapy.

[38]  M. Andrioli,et al.  Isolated corticotrophin deficiency , 2006, Pituitary.

[39]  T. Ogihara,et al.  The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. , 2006, The Journal of clinical endocrinology and metabolism.

[40]  H. Inoko,et al.  Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. , 2000, Tissue antigens.